Title:
CD3 BINDING POLYPEPTIDES
Document Type and Number:
WIPO Patent Application WO/2017/053469
Kind Code:
A3
Abstract:
The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
More Like This:
| JPWO2006132192 | New 2-quinolone derivative |
| JP2001220390 | CONDENSED PYRAZOLE DERIVATIVE |
| JP2013519729 | Aminothiazolone as an estrogen-related receptor α modulator |
Inventors:
TAN PHILIP (US)
BLANKENSHIP JOHN W (US)
BLANKENSHIP JOHN W (US)
Application Number:
PCT/US2016/052942
Publication Date:
May 04, 2017
Filing Date:
September 21, 2016
Export Citation:
Assignee:
APTEVO RES AND DEV LLC (US)
International Classes:
A61K31/496; A61K39/395; C07K16/30; C07K16/40
Domestic Patent References:
| WO2016094873A2 | 2016-06-16 | |||
| WO2013158856A2 | 2013-10-24 | |||
| WO2016014974A2 | 2016-01-28 |
Foreign References:
| US20140088295A1 | 2014-03-27 |
Other References:
ANASETTI ET AL.: "Induction of specific nonresponsiveness in unprimed human T cells by anti- CD 3 antibody and alloantigen", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 172, no. 6, 1 December 1990 (1990-12-01), pages 1691 - 1700, XP055378608
Attorney, Agent or Firm:
MCLEOD, Bonnie Weiss et al. (US)
Download PDF: